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Abstract 
Objective  
The aim of the present cross-sectional study was to examine the association between physical 
activity (PA), sedentary time (ST) and cardio-metabolic risk in adults with pre-diabetes.  
Design and Methods  
Participants (n=2,326; 25-70 years, 67% female) from eight countries with a body mass index 
(BMI) >25 kg·m-2, impaired fasting glucose (IFG; 5.6–6.9 mmol·l-1) and/or impaired glucose 
tolerance (IGT; 7.8–11.0 mmoll-1 at 2 hr) participated. Seven-day accelerometry objectively-
assessed PA levels and sedentary time.  
Results  
Multiple linear regression revealed that moderate-to-vigorous physical activity (MVPA) was 
negatively associated with homeostatic model assessment of insulin resistance (HOMA-IR) 
(standardized β = -0.078 [-0.128,-0.027]), waist circumference (WC); β=-0.177 [-0.122,-
0.134]), fasting insulin (β=-0.115 [-0.158,-0.072]), 2-hour glucose (β=-0.069 [-0.112,-0.025]), 
triglycerides (β=-0.091 [-0.138, -0.044]) and C-reactive protein (CRP; β=-0.086 [-0.127,-
0.045]). Sedentary time was positively associated with HOMA-IR (β=0.175 [0.114,0.236]), 
WC (β=0.215 [0.026,0.131]), fasting insulin (β=0.155 [0.092,0.219]), triglycerides (β=0.106 
[0.052,0.16]), CRP (β=0.106 [0.39,0.172]), systolic blood pressure (BP) β=0.078 
[0.026,0.131]) and diastolic BP (β=0.106 [0.39,-0.172]). Associations reported between total 
PA (counts·minute-1) and all risk factors were comparable or stronger than MVPA; HOMA-IR 
(β=-0.151 [-0.194,-0.107]), WC (β=-0.179 [-0.224,-0.134]), fasting insulin (β=-0.139 [-0.183,-
0.096]), 2-hour glucose (β=-0.088 [-0.131,-0.045]), triglycerides (β=-0.117 [-0.162,-0.071]) 
and CRP (β=-0.104 [-0.146,-0.062]).  
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Conclusions  
In adults with pre-diabetes, objectively measured PA and ST were associated with cardio-
metabolic risk markers. Total PA was at least as strongly associated with cardio-metabolic risk 
markers as MVPA, which may imply that the accumulation of total PA over the day is as 
important as achieving the intensity of MVPA.  
 
 
 
 
Introduction   
The global prevalence of diabetes among adults has almost quadrupled since 1980 to 422 
million cases in 2014 and continued growth is expected (1). This dramatic rise in prevalence is 
largely due to the increase in type 2 diabetes which accounts for the majority of all diagnosed 
cases in adults (1). Changes in lifestyle factors such as sedentary behaviour, insufficient PA, 
dietary choices and excess weight are important contributors in the development of type 2 
diabetes (2). Physical activity plays an important role, independent of weight, in the prevention 
of type 2 diabetes through its effect on insulin resistance (3). Physical activity leads to the 
translocation of GLUT-4 transporters to the plasma membrane increasing glucose uptake into 
skeletal muscle (4). Sedentary time has also been associated with insulin resistance and fasting 
triglyceride levels, independent of PA and obesity (5). Sedentary time is thought to affect 
carbohydrate metabolism by decreasing muscle GLUT-4 concentrations while also reducing 
lipoprotein lipase (LPL) activity and triglycerides clearance (6,7).  
Light activity is also associated with cardio-metabolic health and together with sedentary time, 
occupies the majority of waking hours (8). Indeed, light-intensity activity substantially 
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contributes to overall daily energy expenditure and may also mean spending less time in 
sedentary behaviours.  
Many studies reporting associations between PA, ST and cardio-metabolic risk factors are 
limited by the self-reported measures of PA and ST (9,10) which are susceptible to reporting 
and recall bias. In the limited number that have used objective measures of PA, investigations 
of international samples measured concurrently with the same protocol are lacking, little 
consistency exists with regards to the devices, wear time criteria, intensity cut points or epoch 
lengths used, thereby limiting the ability to make comparisons between these studies. 
Furthermore, despite those with pre-diabetes being at the highest risk of developing type-2 
diabetes and representing the population at which many lifestyle interventions are targeted, few 
studies have described the relationship between PA and insulin resistance in this population.   
Typically, epidemiological research assessing the effect of PA and ST on cardio metabolic risk 
factors has been conducted in the general population (8,11,12). The few studies conducted in 
high risk populations have included participants based on a risk score questionnaire (5), family 
history of type 2 diabetes (9,13) or participants diagnosed with diabetes and pre-diabetes have 
been combined (14). Consequently, physical characteristic and metabolic parameters of study 
participants varied substantially. As a result, it is unclear to what extent reported associations 
could be inferred to individuals with pre-diabetes.  
Therefore, the purpose of this study was to quantify the relationship between objectively 
measured PA and ST with cardio metabolic health and risk of diabetes. 
 
Methods  
Participants and setting  
A detailed account of the PREVention of diabetes through lifestyle Intervention and population 
studies in Europe and around the World (PREVIEW) project has been published elsewhere 
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(15). Participants were recruited into the PREVIEW project between June 2013 and February 
2015. The PREVIEW study is a large multi-national diabetes prevention intervention being 
conducted at eight study sites: University of Copenhagen (Denmark), University of Helsinki 
(Finland), University of Maastricht (The Netherlands), University of Nottingham (UK), 
University of Navarra (Spain), Medical University of Sofia (Bulgaria), University of Sydney 
(Australia) and University of Auckland (New Zealand). 
Participants were selected through an internet-based pre-screening tool or telephone interview 
using the Finnish Diabetes Risk Score (16). A total of 15,611 individuals were contacted for 
pre-screening. Potential participants were sent a written description of the trial, given verbal 
information at the study site and signed informed consent prior to a laboratory screening. The 
laboratory screening was attended by 5,472 participants and included assessment of body mass, 
stature, resting blood pressure (BP), and a 2-hour OGTT (17). Glucose concentrations were 
analysed at each study site (HemoCue™, Angelholm, Sweden; Reflotron™, Roche diagnostics, 
Switzerland; or EML105 Radiometer, Copenhagen) to identify people with pre-existing 
diabetes.  
At the end of this process, 2,326 participants met the following inclusion criteria and found 
eligible to take part in the study: age 25 – 70 years; BMI >25 kg/m2; pre-diabetes confirmed at 
OGTT. Pre-diabetes was defined in line with WHO/IDF and ADA criteria (17) as either (i) IFG, 
with venous plasma glucose concentration of 5.6 – 6.9 mmol·l-1 and/or (ii) IGT, with venous 
plasma glucose concentration of 7.8 – 11.0 mmol·l-1 at 2 hours and fasting plasma glucose <7.0 
mmol·l-1. Participants were free of pre-existing type 2 diabetes, and any illness and/or 
medication with potential effect on compliance or the outcomes of the study. 
 
 
Measurements and procedures 
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Physical activity  
Participants wore an ActiSleep+ (ActiGraph LLC, Pensacola, FL) accelerometer attached to an 
elastic waist belt worn over the right mid-axillary line. The ActiSleep+ was worn 24 h·day-1 for 
seven consecutive days, removing only for water-based activities. The principal output from 
the ActiSleep+ is an activity count, which represents raw accelerations that have been rescaled 
and filtered. Activity counts were collected at 100Hz and aggregated to 60-second epochs (18). 
Sleep time was determined using a fully-automated algorithm developed for use in 24-hour 
waist-worn accelerometer protocols. The algorithm produces estimates of nocturnal sleep 
period that are compared to an expert visual inspection of accelerometer trace (19). After the 
removal of nocturnal sleep episodes, participants were included in the analyses if they wore the 
monitor for  ≥10 hours on ≥4 days (18) including 1 weekend day (20). Mean activity count 
during valid wear time (counts·minute-1; CPM) has been shown to correlate well with total 
activity energy expenditure measured by the doubly labelled water technique (21) and was used 
as an indicator of total PA volume (18, 28). Troiano cut points (18) were used to determine time 
(minutes·day-1) spent at different  intensity categories (Sedentary <100, moderate <2,020 and 
vigorous <5,999 counts per minute). Moderate and vigorous activity were summed to obtain 
moderate to vigorous physical activity (MVPA).  
 
Cardio-metabolic risk factors 
In all study centres, standardized procedures were followed and measurements were performed 
by trained personnel. Self-administered questionnaires, accelerometer data and fasting blood 
samples, were collected at baseline. Blood was drawn from the vein in the antecubital fossa 
after fasting (>10 hours). Blood samples were initially stored locally at -80oC, then transported 
and analysed centrally at the National Institution for Health and Welfare (THL) in Helsinki, 
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Finland where they were analysed for insulin, HbA1c, glucose, high sensitivity C-reactive 
protein (hs-CRP), total cholesterol, triglycerides, HDL-cholesterol (HDL-C) and LDL-
cholesterol (LDL-C) concentrations. Insulin resistance was calculated using the homeostasis 
model assessment for insulin resistance, HOMA-IR using the equation: HOMA-IR= Fasting 
insulin (mU·l-1) x Fasting glucose (mmol·l-1) / 22.5. HOMA-IR has been validated against the 
gold standard hyperinsulinemic-euglycemic clamp technique (23). Total adiposity was assessed 
by dual energy X-ray absorptiometry (DEXA) in four (Copenhagen, Nottingham, Sydney and 
Auckland), bioelectrical impedance in 3 (Helsinki, Sofia, and Navarra) and with Bodpod 
(Maastricht) in one site. Self-administered questionnaires assessed general and socio-economic 
variables, including ethnicity, educational status, household income. 
 
Statistical analysis  
Descriptive statistics (mean ± SD) were calculated for continuous variables and frequencies 
(%) for categorical variables.  
Two-fifths of the participants had a missing value on at least one variable, HOMA-IR was 
missing in 7.8% of all cases, while 17% of values were missing for the accelerometer values 
(CPM, MVPA, and sedentary time). Multiple imputation with fully conditional specification 
model (Markov chain Monte Carlo) was used to impute missing values. All variables were 
included in the imputation and all variables with skewed distribution were log10 or square root 
transformed prior to imputation (24). Ten multiple imputed data sets were generated and pooled 
estimates were reported. Due to their positively skewed distribution, HDL-C, triglycerides hs-
CRP, and waist circumference were logarithmically transformed (log10) while HOMA-IR was 
square root transformed.  
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Separate multiple linear regression models were performed to test the independent association 
between MVPA, CPM and ST with cardio-metabolic health markers (HOMA-IR, fasting 
insulin, FPG, 2h glucose, HbA1c, waist circumference, triglycerides, total C, HDL-C and LDL-
C-) and CRP while adjusting for potential confounders.  
 
Model 1 was adjusted for age, sex, ethnicity (Caucasian, Asian, Black, Arabic, Hispanic or 
other), smoking (daily, less than weekly, no smoker), accelerometer wear time, intervention 
centre, sleep duration, body fat%, education level (no formal education, primary/junior school, 
secondary school, secondary vocational education, higher vocational education or university 
education) and household income (less than £9360, £9360 - £12,479.99, £12,480 - £15,599.99, 
£15,600 - £18,719.99, £18,720 -£22,879.99, £22,880 - £27,559.99, £27,560 - £32,759.99, 
£32,760 – £41,079.99, £41,080 – £53,559.99, £53,560 or more per year). Model 2 was 
additionally adjusted for ST while MVPA was the main exposure variables or for MVPA when 
ST was the main exposure variable.  
Sex, age (<45.9, 46-54.9, >55 years), BMI and intervention centre differences in the 
associations between MVPA, sedentary time, or CPM and each cardio-metabolic risk factor 
were tested for by adding interaction terms to the model.  
A variance inflation factor < 4 confirmed that multicollinearity was not a concern (25). Square 
root and log-transformations were directly compared across cardio-metabolic markers, and 
results of linear regression analysis presented as standardised beta coefficients. Data were 
analysed using the Statistical Package for the Social Sciences version 22.0 (SPSS Inc., Chicago, 
IL, USA) and alpha was set to p < .05.  
 
Results  
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Table 1 displays the descriptive physical and biochemical characteristics of the 2,326 
participants (32% male, age 52.2 ± 11.5 years). Waking accelerometer wear time was  
928.40 ± 83.37 and 933.10 ± 83.85 minutes/day for men and women respectively. Mean ST 
was 617.54 ± 98.06 for men and 579.46 ± 91.76 min/day for women. Mean MVPA was 31.58 
± 20.62 min/day for men and 26.18 ± 17.03 min/day for women. Only 50% of participants met 
the recommended guidelines of 30 minutes of MVPA per day (26).  
Tables 2, 3 and 4 show the standardized regression coefficients of CPM, MVPA and ST with 
the cardio metabolic risk factors. 
 
 
Counts per minute 
Table 2, shows the standardized regression coefficients of CPM, with the cardio metabolic risk 
factors. After adjusting for age, sex, ethnicity, smoking, accelerometer wear time, intervention 
centre, sleep duration, body fat%, education level and household income, CPM had significant 
inverse associations with HOMA-IR, waist circumference, fasting insulin, 2-hour glucose, 
triglycerides and CRP and a positive association with HDL-cholesterol.  
 
MVPA  
Table 3, shows the standardized regression coefficients for MVPA with the cardio metabolic 
risk factors. In model 1, adjusted for age, sex, ethnicity, smoking, accelerometer wear time, 
intervention centre, sleep duration, body fat%, education level and household income, MVPA 
was significantly and negatively associated with HOMA-IR, waist circumference, fasting 
insulin, 2h glucose, triglycerides and CRP) and positively associated with HDL-cholesterol.  
After adjusting for ST in model 2, the association with HDL-cholesterol was lost. Associations 
with other biochemical factors were slightly attenuated but all remained significant.  
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Sedentary time   
Table 4, shows the standardized regression coefficients for ST with the cardio metabolic risk 
factors. In model 1, adjusted for age, sex, ethnicity, smoking, accelerometer wear time, 
intervention centre, sleep duration, body fat%, education level and household income, ST was 
positively associated with waist circumference, systolic BP, diastolic BP, mean arterial 
pressure, fasting insulin, 2 h glucose, HOMA-IR, triglycerides and CRP, and negatively 
associated HDL. After adjusting for MVPA in model 2, associations with 2-hour plasma 
glucose were no longer significant.  
Fasting plasma glucose, total cholesterol and LDL-cholesterol were not associated with any of 
our exposure variables.  
Two-way interactions indicate that associations between MVPA and fasting insulin were 
greater in the older age group (table 3). We did not observe any significant sex, centre, or BMI 
interactions between measures of PA or ST and any cardio metabolic risk factors.  
Conclusions 
This study investigated the associations between objectively measured PA and ST and 
metabolic variables in a worldwide sample of overweight and obese adults (BMI >25 kg/m2) 
with pre-diabetes confirmed through an OGTT (27). To our knowledge this is the first 
international investigation of associations between objectively measured PA and ST with 
cardio-metabolic risk factors in a population that exclusively meet the criteria for pre-diabetes 
(IFG 5.6-6.9 or IGT 7.8-11 (mmol·l-1). Previous studies conducted in high risk populations 
have included participants based on a risk score questionnaire (5), family history of type 2 
diabetes (9,13) or participants with diabetes and pre-diabetes have been combined (14). 
Consequently, physical characteristics and metabolic parameters reported in these studies 
varied substantially from the present study. In our population of participants with pre-diabetes, 
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MVPA was negatively associated with HOMA-IR, waist circumference, fasting insulin, 2h 
glucose, triglycerides and CRP after accounting for potential confounders, sleep duration and 
sedentary time. Our study also demonstrated that total PA volume (counts·minute-1) was at least 
as strongly associated with the aforementioned risk factors as MVPA.  
Before controlling for sedentary time in model 2, total PA volume also accounts for greater 
variance in cardio-metabolic risk factors than MVPA. Hence, it appears that in this population 
although both are significant, the accumulation of total PA over a day is a stronger indicator of 
insulin resistance and some related cardio metabolic risk factors than MVPA.  
Previous studies in populations with a family history of diabetes and newly diagnosed diabetes, 
have shown that total energy expenditure spent on PA (14), counts·minute-1 (13) and MVPA 
(9) were negatively associated with waist circumference, fasting serum triglycerides, systolic 
BP, fasting plasma glucose, fasting plasma insulin,  HOMA-IR and a clustered metabolic risk 
score. In agreement with our findings, Ekelund et al (13), reported that total counts·day-1 was 
more strongly associated with clustered risk and individual cardio metabolic risk factors than 
MVPA. In the general population, Balkau and colleagues (22) reported associations between 
MVPA and total PA with insulin resistance using the gold standard clamp technique for 
determining insulin sensitivity. However, after adjusting for total PA, associations with MVPA 
were lost (22). These findings, in keeping with the present study would support the hypothesis 
that the accumulation of total PA volume accounts for greater variance in insulin resistance and 
some related cardio metabolic risk factors than MVPA.   
The present study also demonstrated that after controlling for confounders, ST is positively 
associated with waist circumference, systolic BP, diastolic BP, fasting insulin, HOMA-IR, 
triglycerides, CRP, and HDL-cholesterol independent of time spent in MVPA.  
In agreement with our findings, Henson et al (5) reported positive associations between ST, 2 
hour plasma glucose, triglycerides and HDL-cholesterol, independent total PA in a population 
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at risk of type 2 diabetes (5). Similarly, positive associations between ST, waist circumference, 
insulin, HOMA-IR and HDL-cholesterol were reported in an older sample with newly 
diagnosed type-2 diabetes (28). There is a lack of consensus on the role of ST in pathology of 
cardio metabolic risk factors. Some authors have reported that once total energy expenditure is 
taken into account the association between ST and cardio-metabolic health are lost.  These 
findings suggest that ST reduces total energy expenditure by displacing other activities that are 
more energy costly (22,29). Other investigators have found that the mechanism linking ST to 
glucose metabolism and metabolic health differ from those of PA and may be related to static 
posture and unloading of large skeletal muscle groups when seated (7,30). Sedentary time is 
thought to affect glucose homeostasis and lipid metabolism by reducing muscle GLUT-4 
content and insulin-stimulated glucose uptake (6) while also reducing  LPL activity leading to 
impaired triglyceride and HDL cholesterol metabolism  (7).  
Further light activity is associated with marked improvements in cardio-metabolic health (8) 
while interventions have shown that replacing ST with postural changes such as standing or 
light ambulatory activity can improve glycaemic control to a greater extent than structured 
exercise of the same energy cost (31). In the present analysis, sedentary time was associated 
with HDL cholesterol, however, associations between MVPA and HDL cholesterol were lost 
after controlling for ST.  Similarly, ST was positively associated with systolic and diastolic 
blood pressure independent of MVPA while no association was found between CPM or MVPA 
with either blood pressure variable. Associations between PA, ST and blood pressure variables 
reported by observational studies have been inconsistent (8,12,14). However, experimental 
studies in overweight/obese populations have suggested that a reduction of sedentary time and 
the interruption of prolonged sedentary bouts with light or moderate activity are associated with 
improved systolic and diastolic blood pressure (32).     
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While physical activity guidelines continue to focus on participation in MVPA (26),  our data 
demonstrated that in a population with pre-diabetes, total volume of PA was as strongly 
associated with cardio-metabolic health as MVPA. The implications of this finding may be 
important considering the levels of PA in this population. Light activity may be more readily 
adopted by individuals with pre-diabetes particularly if they are physically inactive, 
overweight/obese, or reluctant to engage in structured exercise (31).  
 
The lack of associations observed for all exposure variables with fasting glucose is consistent 
with previous research (5,8). This finding reflects the fact that the PA predominantly affects 
peripheral insulin sensitivity, which is responsible for lowering blood glucose levels after an 
OGTT when most of the glucose is taken up by skeletal muscle (33).  
 
The strengths of this study are the implementation of a 24h accelerometer wear time protocol 
that resulted in a greater mean waking wear time (15.5 hours) than many studies of a similar 
nature (5,18,28). Longer monitoring duration provides greater reliability of average activity 
estimates. This approach also allowed an objective assessment of sleep time using an algorithm 
to detect sleep onset and wake time from a 24h waist worn accelerometer trace (19). This 
allowed the study team to control for the confounding effects of sleep on cardio metabolic risk 
factors (34).    
Type 2 diabetes is high on public health agendas with attention on the prevention or delay of 
diabetes onset and the management of cardio metabolic risk factors (35,36). National and 
international guidelines focus on first identifying high-risk individuals and second controlling 
modifiable risk factors such as body weight, diet, ST and PA, through targeted interventions 
(37,38). This study provides new evidence of associations between PA and ST with cardio 
metabolic markers in a population to which the results are most applicable.  
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Whilst this study has numerous strengths it is also important to acknowledge its limitations. 
First, the cross-sectional design does not allow insight into the direction of causality between 
each exposure variable and markers of cardio metabolic health and, although we controlled for 
many potential confounding factors, we did not account for dietary intake or alcohol 
consumption which may have influenced our results. Secondly, although accelerometers offer 
more robust assessments of PA than self-report (39), they are not without limitation. Hip worn 
accelerometers capture most movement during locomotion, but cannot account for upper body 
movement,  movement that occurs during activities such as cycling or weight lifting (40) or 
distinguish between light intensity activities such as sitting and standing. Furthermore, the 
accelerometer is removed during water-based activities and contact sports. Therefore, PA may 
be underestimated. Given the fixed nature of accelerometer-derived variables (sleep, light 
activity ST and MVPA) as proportions of wake time, time spent in behaviours within the day 
are inherently collinear; every increase in time spent in one behaviour unavoidably causes a 
decrease in the time spent in one or a combination of the other behaviours. Thus, it is not 
possible to include all subcomponents of the day (sleep, sedentary, light activity, MVPA) in a 
regression model without violating collinearity assumptions. Consequently, in the present study 
it is not possible to say with certainty that the positive associations observed between cardio-
metabolic risk factors and ST are truly independent and not, in fact, negative associations with 
light activity. Finally, participants in this study were volunteers to a lifestyle intervention from 
the 8 study sites worldwide, approximately 50% of the study sample were between 55-70 years. 
Whilst this may limit the applicability of the current findings to the older age-range, it is this 
group who are at greater risk of type 2 diabetes and are perhaps more likely to participate in 
such interventions given their greater availability of time to those still in employment.  
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In conclusion, this study provides new evidence that in a large diverse population of adults with 
pre-diabetes, objective measures of PA and ST are associated with markers of cardio metabolic 
health. Furthermore, associations with total PA volume are at least as strong as MVPA. Taken 
together, these findings suggest that replacing ST with light activity may provide practical 
approach to improve cardio-metabolic health in a population with low engagement in MVPA.  
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Table 1 Descriptive, metabolic and physical activity characteristics of 2,326 pre-diabetic adults 
from the PREVIEW study 
 Characteristics  Female (n=1570) Male (n= 755) 
Age (years) 51.6 ± 11.6 53.5 ± 11.6 
Height (m) 1.64 ± 0.07 1.77 ± 0.07 
Weight (kg) 95.88 ± 20.33 108.87 ± 20.98 
BMI (kg·m2) 35.70 ± 6.76 34.55 ± 6.01 
Fat (%) 46.45 ± 5.85 36.67 ± 6.92 
Waist (cm) 107.7 ± 14.6 116.8 ± 14.5 
Systolic BP (mmHg) 126.98 ± 5.88 133.10 ± 14.8 
Diastolic BP (mmHg) 77.07 ± 11.15 80.88 ± 9.96 
Fasting insulin (mU·l-1) 12.53 ± 6.54 14.03 ± 6.68 
Fasting plasma glucose (mmol·l-1) 6.08 ± 0.67 6.33 ± 0.66 
2 h plasma glucose (mmol·l-1) 7.64 ± 2.21 7.73 ± 2.24 
HbA1c (mmol·l-1) 36.61 ± 4.03 36.73 ± 4.06 
HbA1c (%) 5.50 ± 0.37 5.51 ± 0.37 
HOMA-IR 3.44 ± 1.90 4.00 ± 2.01 
Triglycerides (mmol·l-1) 1.45 ± 0.77 1.62 ± 0.82 
Total cholesterol (mmol·l-1) 5.25 ± 0.99 5.03 ± 0.97 
HDL-cholesterol (mmol·l-1) 1.33 ± 0.29 1.15 ± 0.23 
LDL-cholesterol (mmol·l-1) 3.28 ± 0.84 3.16 ± 0.85 
CRP (mg/l) (mg·l-1) 4.81 ± 4.02 3.46 ± 3.35 
Accelerometer variables    
Waking wear Time (minutes·day-1) 933.10 ± 83.85 928.40 ± 83.37 
Sleep (minutes·day-1) 474.69 ± 80.26 471.83 ± 85.16 
Sedentary (minutes·day-1) 579.46 ± 91.76 617.54 ± 98.06 
Light (minutes·day-1) 320.84 ± 82.62 280.12 ± 78.20 
Moderate (minutes·day-1) 25.30 ± 6.88 30.33 ± 20.33 
MVPA (minutes·day-1) 26.18 ± 17.03 31.58 ± 20.62 
CPM (counts·minute-1) 294.30 ± 96.77 297.98 ± 17.28 
Ethnicity   
Caucasian (%) 86.02 89.9 
Asian (%) 2.66 2.71 
Black (%) 1.82 1.2 
Arabic (%) 0.2 0.3 
Hispanic (%) 2.33 1.38 
Other (%) 6.61 4.25 
Smoking    
Yes (Daily) (%) 10.72 9.57 
Sometimes (less than weekly) (%) 3.3 2.93 
No (%) 85.98 87.48 
Education    
No formal education (%) 0.5 -- 
Primary/junior school (%) 2.1 2.8 
Secondary school (%) 15.1 14.2 
Secondary vocational education (%) 17.7 19.2 
Higher vocational education (%) 16.4 18.6 
University education  40.5 35.6 
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Other  7.6 9.7 
Household income (per year)   
less than £9360, (%) 8.8 5.3 
£9360 - £12,479.99 (%) 5.8 2.9 
£12,480 - £15,599.99 (%) 5.1 2.5 
£15,600 - £18,719.99 (%) 6.5 3.5 
£18,720 -£22,879.99 (%) 5.7 4.6 
£22,880 - £27,559.99 (%) 8.1 5.9 
£27,560 - £32,759.99 (%) 10.6 8.1 
£32,760 – £41,079.99 (%) 11.2 10.9 
£41,080 – £53,559.99 (%) 13.4 14.2 
£53,560 or more (%) 24.9 42 
 
BMI, body mass index; BP, blood pressure; HbA1c, haemoglobin A1c; HOMA-IR, homeostatic model 
assessment of insulin resistance; HDL, high density lipoprotein; LDL, low density lipoprotein; CRP, C-
reactive protein; MVPA, moderate to vigorous physical activity; CPM, counts per minute. 
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Table 2 Standardized β coefficients for associations between total physical activity 
(counts·minute-1) and cardio metabolic risk factor 
 Characteristics  B 95% Confidence Interval p R2 
Waist (cm) -0.179 (-0.224, -0.134) *** 0.2057 
Systolic BP (mmHg) -0.033 (-0.074, 0.007)  0.1927 
Diastolic BP (mmHg) -0.02 (-0.057, 0.017)  0.3448 
Fasting insulin (mU·l-1) -0.139 (-0.183, -0.096) *** 0.1293 
Fasting glucose (mmol·l-1) -0.028 (-0.074, 0.018)  0.1647 
2 h plasma glucose (mmol·l-1) -0.088 (-0.131, -0.045) *** 0.1139 
HbA1c (%) -0.049 (-0.098, -0.001)  0.1337 
HOMA-IR -0.151 (-0.194, -0.107) *** 0.1306 
Triglycerides (mmol·l-1) -0.117 (-0.162, -0.071) *** 0.0812 
Total cholesterol (mmol·l-1) -0.007 (-0.053, 0.038)  0.095 
HDL (mmol·l-1) 0.088 (0.048, 0.129) *** 0.1856 
LDL (mmol·l-1) 0.002 -0.045, 0.049)  0.0566 
CRP (mg·l-1) -0.104 (-0.146, -0.062) *** 0.2657 
 
 
 
BP, blood pressure; HbA1c, haemoglobin A1c; HOMA-IR, homeostatic model assessment 
of insulin resistance; HDL, high density lipoprotein; LDL, low density lipoprotein; CRP, C-
reactive protein. Adjusted for age, sex, ethnicity, smoking, household income, education 
level, body fat%, wear time, sleep time and intervention centre. *P<0.05; **P<0.01; 
***P<0.001 
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Table 3 Standardized β coefficients for associations between 
MVPA (minutes·day-1) and cardio metabolic risk 
factors 
 Characteristics  B 95% Confidence 
Interval  
p R2 
Model 1     
Waist (cm) -0.177 (-0.122, -0.134) *** 0.2046 
Systolic BP (mmHg) -0.005 (-0.047, 0.083)  0.1915 
Diastolic BP (mmHg) -0.007 (-0.044, 0.031)  0.3441 
Fasting insulin (mU·l-1) -0.115 (-0.158, -0.072) *** 0.1237 
Fasting glucose (mmol·l-1) -0.028 (-0.072, 0.017)  0.1645 
2 h plasma glucose (mmol·l-1) -0.069 (-0.112, -0.025) ** 0.1108 
HbA1c (%) -0.046 (-0.096, 0.004)  0.1334 
HOMA-IR -0.122 (-0.166, -0.078) *** 0.1235 
Triglycerides (mmol·l-1) -0.091 (-0.138, -0.044) *** 0.0762 
Total cholesterol (mmol·l-1) -0.01 (-0.056, 0.035)  0.0952 
HDL (mmol·l-1) 0.055 (0.009, 0.101) * 0.1808 
LDL (mmol·l-1) 0.002 (-0.044, 0.048)   0.0567 
CRP (mg·l-1) -0.086 (-0.127, -0.045) *** 0.262 
Model 2      
Waist (cm) -0.127 (-0.173, -0.081) *** 0.2215 
Systolic BP (mmHg) 0.02 (-0.026, 0.067)  0.1961 
Diastolic BP (mmHg) 0.011 (-0.03, 0.053)  0.3467 
Fasting Insulin (mU·l-1) main effect -0.078 (-0.127, -0.03) ** 0.1337 
main effect     
25-45.9 years(reference)  - - - - 
46.0 -54.9 years 0.025 (-0.120, 0.170)  0.1313 
55.0 -71 years -0.098 (-0.195, -0.001) * 0.1313 
Fasting glucose (mmol·l-1) -0.014 (-0.063, 0.035)  0.1659 
2 h plasma glucose (mmol·l-1) -0.053 (-0.1, -0.006) * 0.1129 
HbA1c (%) -0.036 (-0.095, 0.023)  0.1345 
HOMA-IR -0.08 (-0.129, -0.031) ** 0.1368 
Triglycerides (mmol·l-1) -0.067 (-0.117, -0.017) ** 0.0804 
Cholesterol (mmol·l-1) -0.013 (-0.064, 0.037)  0.0953 
HDL (mmol·l-1) 0.028 (-0.081, 0.383)  0.1867 
LDL (mmol·l-1) 0 (-0.053, -0.052)  0.0572 
CRP (mmol·l-1) -0.061 (-0.108, -0.015) ** 0.2665 
 
 
 
Model MVPA, moderate to vigorous physical activity; BMI, body mass index; BP, blood pressure; HbA1c, 
haemoglobin A1c; HOMA-IR, homeostatic model assessment of insulin resistance; HDL, high density 
lipoprotein; LDL, low density lipoprotein; CRP, C-reactive protein. Model1 adjusted for age, sex, ethnicity, 
smoking, household income, education level, body fat%, wear time, sleep time, and intervention centre. 
Model 2 additionally adjusted for sedentary time. *P<0.05; **P<0.01; ***P<0.001 
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Table 4 Standardized β coefficients for associations between 
Sedentary time (minutes·day-1) and cardio metabolic 
risk factors 
 Characteristics  B 95% Confidence 
Interval  
p R2 
Model 1     
Waist (cm) 0.215 (0.146, 0.267) *** 0.2088  
Systolic BP (mmHg) 0.078 (0.026, 0.131) ** 0.1957 
Diastolic BP (mmHg) 0.057 (0.007, 0.106) * 0.3464 
Fasting insulin (mU·l-1) 0.155 (0.092, 0.219) *** 0.1291 
Fasting glucose (mmol·l-1)  0.052 -0.004, 0.108)  0.1656 
2 h plasma glucose (mmol·l-1)  0.072 (0.015, 0.129) * 0.1106 
HbA1c (%) 0.047 (-0.022, 0.117)  0.1332 
HOMA-IR 0.175 (0.114, 0.236) *** 0.1316 
Triglycerides (mmol·l-1) 0.106 (0.052, 0.16) *** 0.0766 
Total cholesterol (mmol·l-1)  -0.006 (-0.062, 0.051)  0.0953 
HDL (mmol·l-1) -0.103 (-0.165, -0.042 *** 0.1859 
LDL (mmol·l-1) -0.007 (-0.062, 0.048)  0.0568 
CRP (mg·l-1) 0.106 (0.039, 0.172) ** 0.2632 
Model 2      
Waist (cm) 0.165 (0.109, 0.221) *** 0.2215 
Systolic BP (mmHg) 0.086 (0.028, 0.143) ** 0.1961 
Diastolic BP (mmHg) 0.061 (0.006, 0.116) * 0.3467 
Fasting insulin (mU·l-1) 0.126 (0.055, 0.198) ** 0.1337 
Fasting glucose (mmol·l-1) 0.047 (-0.014, 0.108)  0.1659 
2 h plasma glucose (mmol·l-1) 0.053 (-0.009, 0.114)  0.1129 
HbA1c (%) 0.034 (-0.045, 0.113)  0.1345 
HOMA-IR 0.145 (0.077, 0.213) *** 0.1368 
Triglycerides (mmol·l-1) 0.08 (0.023, 0.138) ** 0.0804 
Total cholesterol (mmol·l-1) -0.011 (-0.074, 0.052)  0.0953 
HDL (mmol·l-1) -0.093 (-0.163, -0.022) * 0.1867 
LDL (mmol·l-1) -0.007 (-0.069, 0.055)  0.0572 
CRP (mg·l-1) 0.083 (0.01, 0.156) * 0.2665 
 
BMI, body mass index; BP, blood pressure; HbA1c, haemoglobin A1c; HOMA-IR, homeostatic model 
assessment of insulin resistance; HDL, high density lipoprotein; LDL, low density lipoprotein; CRP, C-
reactive protein; MVPA, moderate to vigorous physical activity. Model1 adjusted for age, sex, ethnicity, 
smoking, household income, education level, body fat%, wear time, sleep time, and intervention centre. 
Model 2 additionally adjusted for MVPA.  
*P<0.05; **P<0.01; ***P<0.001 
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